The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

In this episode, we dive deep into the complexities around the treatment of smoldering multiple myeloma. Our guest, Ming-Hei Tai, a clinical oncology pharmacist, provides a comprehensive overview of the current landscape, including the controversies surrounding the AQUILA trial. Ming shares his concerns about the trial design, highlighting the need for trials that prioritize clinically relevant endpoints like overall survival and prevention of end-organ damage, rather than just asymptomatic progression. The discussion also explores the evolving definitions of myeloma and smoldering myeloma, as well as the potential future role of emerging immunotherapies.